Zions Bancorporation (NASDAQ:ZION) lacks adequate capital to keep lending in a severe economic downturn, the Federal Reserve said Thursday in the release of its annual stress tests. Zions Bancorporation (NASDAQ:ZION) shares after opening at $32.55 moved to $32.55 on last trade day and at the end of the day closed at $31.24. Company price to sales ratio in past twelve months was calculated as 2.96 and price to cash ratio as 0.55. Zions Bancorporation (NASDAQ:ZION) showed a negative weekly performance of -0.35%.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) shares fell -1.30% in last trading session and ended the day on $5.32. MACK return on equity ratio is recorded as 349.10% and its return on assets is -80.40%. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) yearly performance is -14.05%.
On March 14, 2014, Dyax Corp. (NASDAQ:DYAX) entered into an Underwriting Agreement with Jefferies LLC, as representative of the several underwriters (the “Underwriting Agreement”), pursuant to which the Company agreed to offer and sell 8,000,000 shares of its common stock in an underwritten public offering at a public offering price of $9.25 per share. Dyax Corp. (NASDAQ:DYAX) shares moved down -5.13% in last trading session and was closed at $8.88, while trading in range of $8.81 – $9.38. Dyax Corp. (NASDAQ:DYAX) year to date (YTD) performance is 17.77%.
Aastrom Biosciences Inc. (NASDAQ:ASTM) announced that Nick Colangelo, President and CEO of Aastrom, will present at the 2014 Regen Med Investor Day on Wednesday, March 26 at 3:15 p.m. EDT at the Metropolitan Club in New York City. Aastrom Biosciences Inc. (NASDAQ:ASTM) weekly performance is 84.90%. On last trading day company shares ended up $6.49. Aastrom Biosciences Inc. (NASDAQ:ASTM) distance from 50-day simple moving average (SMA50) is 78.37%. Analysts mean target price for the company is $22.25.